PMC:7228307 / 44255-44411 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"799","span":{"begin":15,"end":44},"obj":"Gene"},{"id":"800","span":{"begin":46,"end":50},"obj":"Gene"},{"id":"801","span":{"begin":93,"end":100},"obj":"Gene"}],"attributes":[{"id":"A799","pred":"tao:has_database_id","subj":"799","obj":"Gene:1233"},{"id":"A800","pred":"tao:has_database_id","subj":"800","obj":"Gene:1233"},{"id":"A801","pred":"tao:has_database_id","subj":"801","obj":"Gene:2214"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T371","span":{"begin":19,"end":28},"obj":"Body_part"},{"id":"T372","span":{"begin":114,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A371","pred":"fma_id","subj":"T371","obj":"http://purl.org/sig/ont/fma/fma241981"},{"id":"A372","pred":"fma_id","subj":"T372","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T27","span":{"begin":114,"end":136},"obj":"Body_part"},{"id":"T28","span":{"begin":122,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T783","span":{"begin":93,"end":95},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T784","span":{"begin":114,"end":136},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T785","span":{"begin":114,"end":136},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T786","span":{"begin":114,"end":136},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"799","span":{"begin":15,"end":44},"obj":"Gene"},{"id":"800","span":{"begin":46,"end":50},"obj":"Gene"},{"id":"801","span":{"begin":93,"end":100},"obj":"Gene"}],"attributes":[{"id":"A801","pred":"pubann:denotes","subj":"801","obj":"Gene:2214"},{"id":"A800","pred":"pubann:denotes","subj":"800","obj":"Gene:1233"},{"id":"A799","pred":"pubann:denotes","subj":"799","obj":"Gene:1233"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T253","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T26","span":{"begin":114,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T502","span":{"begin":17,"end":44},"obj":"Protein"},{"id":"T508","span":{"begin":46,"end":50},"obj":"Protein"}],"attributes":[{"id":"A502","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/Q9ULY7"},{"id":"A503","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/Q9ULY6"},{"id":"A504","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/Q8MJW8"},{"id":"A505","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/Q14A03"},{"id":"A506","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/P51680"},{"id":"A507","pred":"uniprot_id","subj":"T502","obj":"https://www.uniprot.org/uniprot/P51679"},{"id":"A508","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/Q9ULY7"},{"id":"A509","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/Q9ULY6"},{"id":"A510","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/Q8MJW8"},{"id":"A511","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/Q14A03"},{"id":"A512","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/P51680"},{"id":"A513","pred":"uniprot_id","subj":"T508","obj":"https://www.uniprot.org/uniprot/P51679"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T370","span":{"begin":19,"end":28},"obj":"Body_part"},{"id":"T371","span":{"begin":114,"end":136},"obj":"Body_part"}],"attributes":[{"id":"A371","pred":"fma_id","subj":"T371","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A370","pred":"fma_id","subj":"T370","obj":"http://purl.org/sig/ont/fma/fma241981"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T19","span":{"begin":114,"end":136},"obj":"http://purl.obolibrary.org/obo/MAT_0000457"},{"id":"T20","span":{"begin":122,"end":136},"obj":"http://purl.obolibrary.org/obo/MAT_0000026"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T22","span":{"begin":138,"end":146},"obj":"Phenotype"}],"attributes":[{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-sentences","denotations":[{"id":"T253","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T22","span":{"begin":138,"end":146},"obj":"Phenotype"}],"attributes":[{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed"}